Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Orphan Nuclear Receptors
Protein Kinase Inhibitors
Our study suggests that the combination of mitogen-activated protein kinase kinase 1/2 inhibitor and LXR ligand can function as a novel therapy to synergistically reduce atherosclerosis while eliminating LXR-induced deleterious effects.